Purchase Order 75N91020P00926

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation on June 28, 2021, for $17,662.80 to supply a BDT kit for Sanger DNA sequencing. The kit is used by LTG scientific staff to verify the sequence of cloned constructs and to genotype human DNA samples. Performance occurs at Grand Island, New York. The order carries a firm fixed-price structure with an ultimate completion date of July 7, 2021.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for BigDye Terminator V1.1 Cycle Sequencing Kit with a ceiling value of $41,430.40 on September 18, 2017, with ultimate completion on October 2, 2017. Work is performed in Bethesda, Maryland. This firm fixed price purchase order is for laboratory sequencing consumables supporting genetic analysis operations at the Institute.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Life Technologies Corporation for $12,187.66 on August 21, 2020, for genotyping experiments. Performance is at Life Technologies' facility in Grand Island, New York. The order carries a firm fixed price and has an ultimate completion date of October 30, 2020. No set-aside category applies.</p>

<p>The National Cancer Institute issued a delivery order to Life Technologies Corporation on January 13, 2020, with a ceiling value of $42,072.38 for BigDye Terminator V1.1 cycle sequencing kit and reagents and consumables for Applied Biosystems 3500XL and 3730XL genetic analyzers.</p> <p>Place of performance is Carlsbad, CA. The order is firm fixed price and completes April 30, 2020. Life Technologies is a subsidiary of Thermo Fisher Scientific Inc.</p>

The National Cancer Institute issued a delivery order to Life Technologies Corporation on June 6, 2019, with a ceiling value of $43,354.52 for reagents and consumables supporting Applied Biosystems 3500XL and 3730XL genetic analyzers. Place of performance is Grand Island, NY. The order is firm fixed price with an ultimate completion date of July 6, 2019. Life Technologies Corporation is a subsidiary of Thermo Fisher Scientific Inc. and specializes in biomedical research and genetic analysis...

The National Human Genome Research Institute awarded a purchase order to Life Technologies Corporation on August 10, 2019, for $22,278.60, with an ultimate completion date of October 31, 2019. Performance occurs in Bethesda, Maryland. The order is priced on a firm fixed price basis with no set-aside category. Life Technologies supplies laboratory instrumentation, reagents, and consumables to federal research and health agencies; the source does not specify the particular items or quantities...

<p>The National Cancer Institute issued a $32,582.74 delivery order to Life Technologies Corporation on September 17, 2018, for reagents and consumables supporting Applied Biosystems 3500XL and 3730XL genetic analyzers.</p> <p>Place of performance is Grand Island, NY. The order has a ceiling value of $32,582.74 with an ultimate completion date of September 24, 2018. Pricing is firm fixed price. No set-aside was used.</p>

The National Human Genome Research Institute awarded a purchase order to Life Technologies Corporation on March 11, 2019, valued at $11,095.74 for reagents and kits. Place of performance is Grand Island, New York. The order carries a firm fixed price and ultimate completion date of April 30, 2019. Life Technologies Corporation, a wholly owned subsidiary of Thermo Fisher Scientific Inc., is a large business with no small business set-asides, competing on proprietary biomedical research...

The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $14,478.46 on June 24, 2019, for drugs and biologicals with a completion date of July 31, 2019. Work is performed in Grand Island, New York. This firm fixed-price order procures specialized biomedical research instruments, reagents, or consumables typical of Life Technologies' federal supply portfolio—the vendor operates as a direct supplier of genetic analysis instruments, immunoassay systems, flow...

The National Cancer Institute issued a delivery order to Life Technologies Corporation on January 25, 2019, with a ceiling value of $45,930.66 for reagents and consumables supporting Applied Biosystems 3500XL and 3730XL genetic analyzers. Place of performance is Grand Island, NY. The order is priced on a firm fixed price basis and has an ultimate completion date of February 28, 2019. Life Technologies Corporation is a subsidiary of Thermo Fisher Scientific Inc. and a leading provider of...